Corbus Pharmaceuticals Holdings, Inc.
CRBP
$8.83
-$0.22-2.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 109.47% | 93.01% | 121.22% | 171.47% | 25.89% |
| Gross Profit | -109.47% | -93.01% | -121.22% | -171.47% | -25.89% |
| SG&A Expenses | -6.76% | -24.27% | -3.83% | 7.04% | 22.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.26% | 57.48% | 74.30% | 93.90% | 24.75% |
| Operating Income | -74.26% | -57.48% | -74.30% | -93.90% | -24.75% |
| Income Before Tax | -115.69% | -69.35% | -76.67% | -146.09% | -18.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -115.69% | -69.35% | -76.67% | -146.09% | -18.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -115.69% | -69.35% | -76.67% | -146.09% | -18.80% |
| EBIT | -74.26% | -57.48% | -74.30% | -93.90% | -24.75% |
| EBITDA | -75.74% | -58.71% | -76.22% | -96.16% | -25.26% |
| EPS Basic | -59.03% | -65.32% | -59.54% | -67.60% | 56.85% |
| Normalized Basic EPS | -18.02% | -65.33% | -59.53% | -67.62% | 38.74% |
| EPS Diluted | -59.03% | -65.32% | -59.54% | -67.60% | 56.85% |
| Normalized Diluted EPS | -18.02% | -65.33% | -59.53% | -67.62% | 38.74% |
| Average Basic Shares Outstanding | 35.62% | 2.44% | 10.74% | 46.83% | 175.32% |
| Average Diluted Shares Outstanding | 35.62% | 2.44% | 10.74% | 46.83% | 175.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |